VCG
ANIP icon

Vantage Consulting Group’s ANI Pharmaceuticals ANIP Stock Holding History

Vantage Consulting Group’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-2,208
Closed -$64K – 193
2020
Q4 		$64K Buy
+2,208
New +$63.2K 0.01% 358

Other funds holding ANIP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ICOM
Investment Counselors of Maryland Baltimore, Maryland $4.37B AUM 76.25% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
TSW
Thompson Siegel & Walmsley Richmond, Virginia $5.7B AUM 6.69% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
FWSM
First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return

Vantage Consulting Group's ANIP Position: Q1 2021 in Review

Vantage Consulting Group sold out of ANI Pharmaceuticals (ANIP) in Q1 2021, closing a stake of 2,208 shares — an estimated $64K sold.

Vantage Consulting Group first reported a position in ANIP in Q4 2020 and held it in 1 quarter. The position peaked at $64K in Q4 2020. 106 funds tracked by Wall St. Rank hold ANIP as of Q1 2021.

  • Vantage Consulting Group reported no remaining ANI Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Vantage Consulting Group sold 2,208 ANI Pharmaceuticals shares in Q1 2021, an estimated $64K.
  • Vantage Consulting Group first reported a position in ANI Pharmaceuticals in Q4 2020 and held it in 1 quarter.
  • Vantage Consulting Group's ANI Pharmaceuticals position peaked at $64K in Q4 2020.
  • 106 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2021.

Based on Vantage Consulting Group's 13F filing for Q1 2021, filed 14 May 2021.